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ABSTRACT 
PURPOSE. To examine the ability and mechanism of the 16 kDa N-terminal fragment of human prolactin (16K 
hPRL) in the inhibition of abnormal retinal neovascularization. 
METHODS. The 16K hPRL-encoding sequence was inserted into an adenoviral vector (16K-Ad). Western blot 
analysis verified the expression of 16K hPRL and inhibition of proliferation, confirming functional activity of 
the 16K hPRL in virus-infected adult bovine aortic endothelial (ABAE) cells. 16K hPRL inhibited retinal 
neovascularization in a mouse model of oxygen-induced retinopathy. The ability of recombinant 16K hPRL 
expressed in E. coli (r16K hPRL) was compared to that of endostatin in inducing apoptosis of cultured human 
retinal endothelial cells (HREC). 
RESULTS. 16K was expressed in virus-infected ABAE cells and resulted in a dose-dependent inhibition of cell 
proliferation. Eyes injected with 16K-Ad showed a reduction in preretinal neovascularization of 82.3 ± 9.3% (P 
< 0.00001) when compared to uninjected controls. rl6K hPRL was 100 times more potent than endostatin in 
inducing apoptosis in HRECs. 
CONCLUSIONS. Intravitreal administration of 16K hPRL inhibited neovascularization in the mouse model of 
oxygen-induced retinopathy. 16K hPRL stimulated apoptosis in HRECs and inhibited cell proliferation in ABAE 




Proliferative retinopathies, which include retinopathy of prematurity (ROP), proliferative diabetic retinopathy 
(PDR), and "wet" age-related macular degeneration (ARMD), are the leading causes of blindness in the western 
world. The underlying etiology common to these diseases is the proliferation of aberrant blood vessels.1 To date, 
photocoagulation is the mainstay of management of patients with PDR. While effective at reducing severe vision 
loss, there can be serious side effects, including diminished night vision, reduced peripheral vision, and 
decreased visual acuity. Moreover, in some patients the disease progresses despite costly maximal laser therapy. 
ROP therapies are limited to laser and cryosurgery of the avascular zone. Clearly, the development of an 
affordable and efficacious drug therapy for the proliferative retinopathies would be a major breakthrough in 
medicine. 
Vascular endothelial growth factor (VEGF) is currently viewed as the major effector for retinal 
neovascularization in all proliferative retinopathies. One approach in inhibiting neovascularization associated 
with eye disease is the use of antiangiogenic peptides. This concept has been extensively tested in animal 
models. The antiangiogenic peptides shown to inhibit retinal neovascularization in rat and mouse models 
include: angiostatin,2,3 plasminogen kringle 5 fragment,4 thrombospondin type 1 repeat fragments,5 carboxyl-
terminal fragment of tryptophanyl-tRNA synthases,6 and pigment epithelium-derived factor.5 
The study of inhibition of retinal vascularization by antiangiogenic peptides was extended to the antiangiogenic 
factor 16K hPRL for several reasons. 16K hPRL is a naturally occurring, specific antiangiogenic factor that has 
been evaluated in multiple in vitro and in vivo systems.7 16 K hPRL is endothelial cell specific and extremely 
potent. 16K hPRL inhibits VEGF-and fibroblast growth factor-2 (FGF-2)-induced capillary endothelial cell 
growth by blocking activation of the mitogen-activated protein kinase (MAPK) signaling cascade and induces 
apoptosis by inhibiting NF-κB activation.8 
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An adenovirus vector expressing 16K hPRL was developed to test the possibility that this well-characterized 
angiogenic factor could be used to prevent retinal neovascularization.9 Primary cultures of human retinal 
endothelial cells (HREC) were used to test the efficacy of rl6K hPRL to induce apoptosis, a well-characterized 
action of antiangiogenic factors.10 Primary cultures of ABAE cells were infected with the 16K-Ad to show that 
sufficient 16K hPRL was expressed after infection to inhibit endothelial cell proliferation. In vivo studies were 
carried out in the mouse model of oxygen-induced retinopathy.11  This model is well established and resembles 
the human disease with extra retinal neovascularization. Increases in VEGF and VEGF receptors are closely 
correlated with neovascularization in this model.12 l6K-adenoviral infection of the eye dramatically inhibited 
neovascularization in the mouse model of oxygen-induced retinopathy. 
MATERIALS AND METHODS  
Cell Culture 
Human embryonic kidney (HEK) 293 cells, adenoviral E1-transformed HEK cells (BD Biosciences, San Diego, 
CA) were grown in Minimal Essential Medium (MEM) supplemented with 10% fetal calf serum (FCS), 1% 
nonessential amino acids and 100 U/mL penicillin/streptomycin and 2.5 µg/mL fungisome. 
ABAE cells were isolated as previously described.13 The cells were grown and serially passaged in low-glucose 
Dulbecco's modified Eagle's medium (DMEM) containing 10% FCS and 100 U/mL penicillin/ streptomycin and 
2.5 µg/mL fungisome (10% FCS/DMEM medium). Recombinant human FGF-2 (Promega, Madison, WI) was 
added (1 ng/mL) to the culture every other day. Confluent cells corresponding to passages 7 to 12 were used in 
the experiments. 
Primary cultures of HRECs were prepared and maintained in DMEM/Hams F12 with 10% plasma-derived 
serum (PDS), 5 µg/mL transferrin, 2 µg/mL selenium, 1 µg/mL insulin, 0.584 mg/mL glutamine, and 15 mg/mL 
endothelial growth supplement (Sigma, St. Louis, MO)10 and cells in passages 3 to 6 were used in the studies. 
The identity of endothelial cells in cultures was validated by demonstrating endothelial cell incorporation of 
fluorescence-labeled acetylated LDL and by flow cytometry analysis, as previously described.14 To maintain 
purity of HRECs, the cells were grown in PDS, which is free of platelet-derived growth factor and does not 
promote the growth of pericytes (the contaminating cell type in these preparations). r16K hPRL was produced as 
previously described.15 Endotoxin levels in the preparations were 100 times lower than amounts needed to mimic 
the actions of 16K hPRL. Endostatin was obtained from Sigma. 
Construction and Generation of Adenovirus Vectors 
All recombinant adenovirus was prepared using Adeno-X expression system purchased from BD Biosciences. 
The cDNA encoding 16K hPRL was excised from the pRC/CMV-hPRL 16K vector (Fig. 1A).9  This construct 
was engineered to produce a secreted peptide consisting of the first 139 amino acids of the PRL. Codon 140 was 
replaced by a stop codon using PCR-directed mutagenesis.16 Cysteine 58 (TGG) was replaced by a serine (TCC) 
to avoid non-native disulfide bridges. The rabbit β-globin intron was inserted 5' of the 16K hPRL signal peptide. 
The restriction sites NheI and KpnI were added respectively to 5' and 3' ends by PCR. The sense primer was 5'-
GGGCTAGCGATCCT-GAGAACTTCAGGGT-3' and the antisense primer, containing a stop codon 
(underlined), was 5'-CGGTACC[UNDERLN]TCA[/UNDERLN]-AGGATGAACCTGGCTGAC-3'. 
A replication defective adenoviral vector based on human Ad 5 serotype was used for the study. The 16K hPRL 
coding sequence was inserted in the expression cassette into the adenoviral shuttle vector, pShuttle, at the Nhel 
and Kpnl restriction sites and was verified by sequencing. The cytomegalovirus (CMV) promoter drives the 
expression of the expression cassette. The expression cassette was then excised from pShuttle and inserted to 
Adeno-X Viral DNA via the I-CeuI and PI-SceI restriction sites. The recombinant Adeno-X vector (16K-Ad) 
was propagated in HEK 293 cells, purified by cesium chloride density gradient ultracentrifugation, and stored at 
-80 °C. Adenovirus vector titer was determined by tissue culture infectious dose 50 (TCID50). Adenovirus vector 
carrying an empty expression cassette was used as control (Null-Ad). 
Western Blot Analysis 
ABAE cells (1.5 x 104) were plated in 24-well plates in 0.5 mL 10% FCS/DMEM medium. On the following day 
the cells were infected with 16K-Ad or Null-Ad at a multiplicity of infection (MOI) of 200 pfu/cell, and the 
conditioned media were collected 48 hours postinfection. Since the cDNA for 16K hPRL contains a signal 
peptide, 16K hPRL is secreted into the culture medium. Conditioned media (20 µL) was heated in sample buffer 
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containing 1% 2-mercaptoethanol for 5 minutes at 95°C and separated by SDS/PAGE 15%/4% before being 
transferred to a nitrocellulose membrane (Hybond ECL; Amersham, Piscat-away, NJ). The membrane was 
saturated overnight in TBS-8% dry milk, followed by 1 hour of incubation with a 1/200 dilution of polyclonal 
antiserum directed against 16K hPRL (SB30) and 1 hour of incubation with a 1/5000 dilution peroxidase-
conjugated goat antirabbit serum (Gamma; BioWhittaker, Verviers, Belgium). 16K hPRL detection was then 
carried out by chemiluminescence using the ECL Plus kit (Amersham). For the deglycosylation experiments, the 
N-Glycosidase F de-glycosylation Kit was used according to the manufacturer's instructions (Roche, Palo Alto, 
CA). Briefly, 20 µL of conditioned medium from Ad-16K hPRL-infected ABAE cells were incubated with             
10 µL of denaturation buffer for 3 minutes at 95°C. Twenty microliter of reaction buffer and 15 µL of N-
glycosidase F (1.2 units/µL) were added and incubated for 1 hour at 37°C. The deglycosylated product was 
precipitated with two volumes of cold methanol and analyzed by Western blotting as described above. 
Experimental Animals 
All animal procedures used were in agreement with the NLH Guide for the Care and Use of Laboratory Animals, 
with the ARVO Statement for the Use of Animals and with institutional guidelines, and approved by the 
University of Florida Institutional Animal Care and Use Committee. Timed pregnant C57BL/6J mice were 
purchased from Jackson Laboratories (Bar Harbor, ME). 
Intravitreal Injection into Mouse Model 
In the mouse model of oxygen-induced retinopathy,11 mice at postnatal day (P)7 are placed with their nursing 
dams in a 75% oxygen atmosphere for 5 days. On return to normal air, these mice develop retinal 
neovascularization, with peak development occurring 5 days (P17) after their return to normoxia. Newborn mice 
(P1) were chilled on ice for 30 to 45 seconds to reduce their activity. Using a 32G needle attached to a 10 µL 
Hamilton syringe, 0.5 µL of a mixture containing the adeno-construct and 0.1% (v/v) fluorescein sodium 
(Angiofluor: Alliance Pharmaceuticals, Richmond, TX) was injected into the vitreous OD (Ad-16k = 9 x 109 
pfu/mL) or OS (Ad-Null = 2.2 x 1010 pfu/mL); 0.1% fluorescein sodium was used to visualize the injection. After 
the fifth day following return to normoxia, the animals were killed, the eyes removed, fixed in 4% 
paraformaldehyde, and embedded in paraffin. Three hundred serial sections (6 µm) were cut sagitally through 
the cornea parallel to the optic disc. Every thirtieth section was placed on a slide and stained with hematoxylin-
eosin (H&E). This resulted in ten sections from each eye being scored in a masked fashion using light 
microscopy to count endothelial nuclei extending beyond the inner limiting membrane into the vitreous as 
previously described.11 The efficacy of treatment with a particular plasmid was then calculated as the percent 
average nuclei per section in the injected eye versus the uninjected eye. 
For qualitative analysis the retinas from some mice were dissected and flatmounted, as described by D'Amato et 
al.17 These animals were perfused with 3 mL of fluorescein-isothiocynate (FITC)-dextran (FD-2000S; Sigma) in 
4% paraformaldehyde. The eyes were enucleated and the retinas removed and flatmounted for fluorescence 
microscopic analysis. 
In Vitro Endothelial Cell Proliferation Assay 
On day 1, ABAE cells were plated at a density of 1.5 x 104 cells per well in a 24-well plate, in 0.5 mL 10% 
FBS/DMEM medium. On day 2, cells were infected for 4 hours with increasing MOI of adenovirus vector. On 
day 3, the cells were stimulated with FGF-2 (1 ng/mL) for 16 hours. On day 4, the cells were incubated with 5 x 
10 cpm of thymidine for 4 hours,18 washed in 5% trichloroacetic acid, solubilized in NaOH, and counted as 
previously described.16 
 
DNA Fragmentation ELISA Assay 
The levels of mono- and oligonucleosomal DNA released in the cytosol of apoptotic cells were measured using 
the Cell Death Detection ELISA kit (Boehringer Mannheim, Mannheim, Germany). This is a quantitative 
sandwich-enzyme-immunoassay using antibodies against DNA and histones. By isolating nucleosomes in the 
cytosol with antibodies to histones, this assay specifically measures apoptosis and not necrosis. 
For these studies, 100,000 HREC were plated per well in 12-well plates. Twenty-four hours later, rl6K hPRL, 
r23K hPRL, endostatin or endotoxin were added for 24 hours. The Cell Death Detection assay was performed on 
cytosolic fractions prepared using reagents supplied with the kit according to instructions. Levels of DNA 
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fragmentation were expressed as an enrichment factor, calculated by dividing the absorbance of a given sample 
by the absorbance of the corresponding 10% FCS control. 
Statistical Analysis 
All statistical analysis was done using the student t-test in Microsoft Excel. P-values < 0.001 are indicated with 
an asterisk on the graphs. 
RESULTS 
16K-Ad Infected ABAE Cells Express and Secrete Biologically Active 16K hPRL. 
To extend findings with 16K hPRL to an in vivo setting, a 16K-Ad vector was engineered. To validate the 
usefulness of the 16K-Ad vector, ABAE cells were infected to determine that the infected cells expressed and 
secreted substantial amounts of biologically active 16K hPRL. ABAE cells were infected with a MOI of 200 
pfu/cell of 16K-Ad or Null-Ad as a control for viral infection. ABAE cells infected with the 16K-Ad vector 
expressed 16K hPRL (Fig. 1A). Western blot analysis revealed a band running higher than that seen for 
recombinant 16K hPRL produced in Escherichia coli (Fig. 1B), possibly the result of N-glycosylation of Asn31 
within 16K hPRL. After deglycosyla-tion of the conditioned media with N-Glycosidase F, the band co-migrated 
with the rl6K hPRL made in E. coli (Fig. 1C). 
The amount of 16K hPRL produced in 16K-Ad infected ABAE cells, as estimated by Western blot analysis, 
appeared sufficient to obtain a biologically active concentration to inhibit cell proliferation. Consistent with this, 
FGF-2-induced ABAE proliferation was inhibited in a dose-dependent manner with increasing MOI of 16K-Ad 
while Null-Ad had no effect (Fig. 2). 
Reduced Neovascularization by 16K hPRL in Mouse Model of Oxygen-Induced Retinopathy 
The oxygen-induced model of retinopathy11 was used to test the effect of the 16K hPRL in vivo. Mice, at P1, 
were injected in the right eye with the adeno-constructs (Null-Ad or 16K-Ad). The extent of preretinal 
neovascularization was scored by counting the average number of preretinal nuclei per section of eye (Fig. 3). 
Injection of the Null-Ad construct exhibited no significant difference from control (P = 0.41), as expected. The 
16K-Ad construct showed a reduction in the average number of preretinal nuclei per section when compared to 
control left eyes of 66 ± 8% (P = 3 x 10-8). Cross-sections from representative eyes (Fig. 4) confirm the reduction 
in preretinal vessels in mice injected with the 16K-Ad construct. Perfusion of uninjected eyes from mice that 
underwent the time course of the OIR model demonstrated the leaky nature of the preretinal blood vessels that 
resulted from the hypoxic stimulus of this model (Fig. 5A). Injection of the 16K-Ad construct significantly 
reduced the number of leaky vessels in mice subjected to the OIR model (Fig. 5B). No difference in vasculature 
was found between uninjected eyes (Fig 5C) and eyes injected with the 16k-Ad construct (Fig. 5D) from mice 
that had not been subjected to the OIR model. 
16K hPRL-Induced Apoptosis in HRECs 
Increasing concentrations of rl6K hPRL progressively increased the level of DNA fragmentation (Fig. 6). 
Although the stimulation of DNA fragmentation was similar with 20 nM rl6K hPRL and 10 U of endotoxin, 
there was <0.01 U of endotoxin in the 20 nM rl6K hPRL preparation. Endostatin (10 µg/mL, 500 nM) gave the 
same response as 5 nM rl6K hPRL (80 ng/mL); that is, the potency of rl6K hPRL was 100 times greater. 
Although intact 23 kDa prolactin (10 nM) contained similar amounts of endotoxin to the rl6K hPRL preparation, 
it had no effect on DNA fragmentation, as previously reported in human umbilical vein endothelial cells 
(HUVEC) and bovine brain endothelial (BBE) cells.15 
 
FIGURE 1: Construction and characterization of 16K hPRL adenovirus vector:  
(A) Schematic representation of the 16K hPRL expression vector, the I-CeuI/PI-SceI restriction fragment cloned in adenovirus5 genome is 
shown. CMV IE, human cytomegalovirus immediate early promoter/enhancer; β-globin intron, rabbit β-globin intron; 16K hPRL, 16K hPRL 
coding sequence including the signal peptide; polyA, SV40 polyadenylation signal. (B) Analysis of protein expression by Western blot 
analysis from ABAE cells uninfected or infected at an MOI of 200 pfu/cell with 16K-Ad or Null-Ad. Lane 1: E. coli 16K hPRL; lane 2: 
protein from cells infected with 16K-Ad; lane 3: protein from cells infected with Null-Ad. Twenty µL of conditioned media were subjected 
to SDS-PAGE and probed with an anti-PRL antibody. The band corresponding to 16K hPRL (16 kDa) is labeled. Thirty nanograms of 
recombinant 16K hPRL produced in E. coli was loaded as a control. (C) Analysis of glycosylation. Lane 4: E. coli 16K hPRL; lane 5: protein 
from cells infected with 16K-Ad; lane 6: deglycosylated protein from cells infected with 16K-Ad. Twenty microliters of conditioned media 
from 16K-Ad-infected ABAE cells were incubated or not with N-glycosidase and subjected to Western blotting as in B. The band 
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FIGURE 2: Inhibition of endothelial cell proliferation by direct infection of 16K hPRL adenovirus vector.  
ABAE cells were infected with indicated MOI (pfu/cell) of 16K-Ad or Null-Ad and treated, 24 hours later, with FGF-2 (1 ng/mL). 
Proliferation was assessed by 3H-thymidine incorporation 48 hours postinfection. The data are expressed as percentages of the stimulation 
obtained with FGF-2 alone, 0% being the basal growth level. Data are the mean of triplicate wells; bars ± SE. The experiments were repeated 
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FIGURE 3: Results of the injection of the adeno-constructs in the oxygen-induced mouse model of retinopathy.  
The y-axis indicates the average number of nuclei of preretinal endothelial cells per section. For each mouse the right eye (OD) was injected 
with the adeno-construct and the left eye was uninjected. For the 16K-Ad eyes (n = 11) and for the Null-Ad eyes (n = 4). Neovascularization 




FIGURE 4: Retinal cross-sections of eyes from mice that have undergone the oxygen-induced model of 
retinopathy.  
(A) [OS] and (B) [OD] paired eyes from a mouse that received no injection OS and was injected OD with the Ad-Null virus. (C) [OS] and 
(D) [OD] paired eyes from a mouse that received no injection OS and was injected OD with the Ad-16K virus. Only the eye injected with the 
Ad-16K virus shows significant reduction in preretinal nuclei (*). Original magnification, x5 
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FIGURE 5: Flatmounted retinas from mice perfused with FITC-dextran. 
 (A) Retina from an uninjected mouse eye on postnatal day 17 after the OIR timecourse; (B) Retina from a mouse eye injected with the 16K-
Ad construct on postnatal day 17 after the OIR timecourse; (C) Retina from an uninjected normoxic mouse eye on postnatal day 17; (D) 
Retina from a normoxic eye injected with the 16k-Ad construct on postnatal day 17. 
 
 
FIGURE 6: Activation of apoptosis by recombinant 16K hPRL in HREC.  
The level of DNA fragmentation (cytosolic mono- and oligonucleosomes) was measured in HREC treated with increasing concentrations of 
recombinant 16K hPRL produced in E. coli (5, 10, and 20 nM), 10 U of endotoxin or 10 µg/mL endostatin. 
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DISCUSSION 
Vascular retinopathies are significant vision-threatening diseases.19 Occlusion of capillaries leads to retinal 
ischemia. Attempts to reperfuse areas of retinal ischemia with new, albeit aberrant, blood vessels lead to further 
vascular pathology. In all proliferative retinopathies the state of the nonperfused retina produces angiogenic 
growth factors such as VEGF and FGF-2, which stimulate this new, compensatory, blood vessel growth. 
This study explored the effect of the antiangiogenic peptide 16K hPRL in both in vitro and in vivo systems 
relevant to the retina. Previously it was demonstrated that 16K hPRL, but not intact PRL, inhibits VEGF- and 
FGF-2-induced proliferation of a variety of capillary endothelial cells in nM concentrations16,20 including 
endothelial cells isolated from the rat retina.21 The signaling pathways for the antiproliferative action of 16K 
hPRL include the inhibition of VEGF- and FGF-2-induced Ras activation.22 This is consistent with the idea that 
16K hPRL might be particularly efficacious in inhibiting VEGF-driven retinopathy. 
The inhibition of VEGF- and FGF-2-induced proliferation appears to be mediated through blocking of the 
MAPK signaling pathway. Activation and tyrosine phosphorylation of the Flk1 receptor by VEGF are not 
affected by the addition of 16K hPRL23; neither is the association of the receptor with Shc, and Grb2 or the 
recruitment of Sos.22 However, activation of Ras is inhibited. When activated by VEGF alone, Ras is converted 
from the GDP- to the GTP- bound state. This conversion is blocked when 16K hPRL is added to VEGF. The 
blockade of Ras activation is consistent with the downstream inhibition of the VEGF-induced translocation of 
Raf-1 to the plasma membrane and the blockade of the activation of MEK and MAPK 42 and 44.22 
16K hPRL activates apoptosis in capillary endothelial cells,15 inhibits capillary endothelial cell migration, their 
organization into capillaries,16 and urokinase activity.24 Importantly, 16K hPRL inhibits neovascularization in the 
chick chorioallantoic assay,16 rat corneal assay,25 and in solid tumors in mice.9 The 16 K hPRL fragment is 
naturally formed in rodents and in humans by proteolytic processing,26-28 and PRL, the precursor molecule, is 
expressed by retinal endothelial cells.21 16K hPRL had been used successfully in gene therapy to inhibit the 
growth of the HCT116 human colon cancer cell line in immuno-incompetent mice.9 16K hPRL has no direct 
effect on the growth of HCT116 cells, but acts directly on the tissue vasculature. 
The studies described here support the efficacy of this peptide in inhibiting growth of the relevant cell type (i.e., 
HREC). Furthermore, the 16 K hPRL fragment is unique in having endothelial cell specificity. Thus, unlike 
many other anti-angiogenic agents considered for possible therapy, the 16 K hPRL would not be expected to 
affect other cell types adversely in the retina. 
These data demonstrate that 16K hPRL is potent in the nM range to activate apoptosis in HREC. 16K hPRL has 
also been reported to inhibit cell proliferation of rat corneal and retinal endothelial cells.21,25 Clearly, 16K hPRL 
was considerably more potent than the preparation of endostatin tested. This is in close agreement with earlier 
findings that rl6K hPRL stimulates DNA fragmentation in BBE and HUVE cells15 and that activation of 16K 
hPRL-induced apoptosis is dependent on activation of the caspase cascade and can be blocked by the addition of 
caspase inhibitors. The activity of the rl6K hPRL does not involve contamination with endotoxin. Heat 
denaturation of 16K hPRL by boiling, digestion with trypsin, or coincubation with the endotoxin blocker 
polymyxin-B has no effect on the action of 16K hPRL. Furthermore, immuno-neutralization of 16K hPRL with 
specific antibodies to 16K hPRL can block its ability to induce DNA fragmentation in BBE cells. 
These findings with 16K hPRL were extended to an in vivo setting by using an engineered 16K-Ad vector. The 
usefulness of the 16K-Ad vector was validated by first infecting ABAE cells and demonstrating that the infected 
cells secreted substantial amounts of biologically active 16K hPRL. However, the 16K hPRL expressed in 
ABAE cells infected with the 16K-Ad vector was highly N-glycosylated. This is in agreement with observations 
made in HCT116 cells stably transfected with a 16K hPRL expression vector.9 Glycosylated peptide produced in 
both cells was biologically active while the 16K hPRL expressed in E. coli as expected was not glycosylated. 
In conclusion, the ability of 16 K hPRL to inhibit retinal neovascularization was studied because it is a potent 
and specific antiangiogenic factor.20 16K hPRL is a naturally occurring fragment found in rodents26 and in 
humans,27,28 and the parent protein prolactin is specifically expressed by retinal endothelial cells.21 The signaling 
pathways regulating the inhibition of endothelial cell proliferation by 16K hPRL include the unique action of 
inhibiting Ras activation by both VEGF and FGF-2.29 Previously, 16K hPRL was shown to activate apoptosis in 
BBCE.15 But the present study demonstrated that rl6K hPRL was 100 times more potent than endostatin in 
inducing apoptosis in the most relevant cell type, HRECs. 
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Infection of ABAE cells with increasing amounts of 16K-Ad inhibited cell proliferation and eyes injected with 
16K-Ad showed a dramatic reduction in preretinal neovascularization when compared to uninjected controls, 
while having no effect on animals exposed to normoxia. This combination of studies supports 16K hPRL as an 
endothelial cell-specific candidate therapeutic agent for the treatment of aberrant neovascularization of the retina. 
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